Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Clin Case Rep ; 12(1): e8419, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38197063

RESUMEN

Arteriovenous hemangioma is a rare, benign vascular lesion that presents with an asymptomatic red or violaceous papule which is frequently asymptomatic but pruritus, pain and enlargement may be seen in some patients. In histology it is composed of thick-walled and thin-walled blood vessels distributed in superficial and mid dermis. The treatment of choice in such cases is complete excision and recurrence is rare. In this article we describe an acquired form of arteriovenous hemangioma on the nose of a middle-aged man.

2.
J Dermatol ; 50(10): 1357-1362, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-37269152

RESUMEN

Pathogenic variants in the EDARADD gene result in autosomal recessive and autosomal dominant ectodermal dysplasia. This article reports on the fourth family in the world with ectodermal dysplasia 11A (ECTD11A) cause from a novel splicing variant in the EDARADD gene, identified by whole exome sequencing and confirmed by Sanger sequencing. The proband and his mother were heterozygous for the detected variant (NM_145861.4:c.161-2A>T). The proband manifests unusual symptoms including hyperkeratotic plaques, slow-growing hair, recurrent infection, and pectus excavatum. His mother presents hypohidrosis, extensive tooth decay, fragile nails, and sparse hair. Further studies on ECTD11A patients could be useful to characterizing the phenotype features more precisely.


Asunto(s)
Displasia Ectodérmica , Receptor Edar , Femenino , Humanos , Receptor Edar/genética , Receptor Edar/metabolismo , Linaje , Displasia Ectodérmica/diagnóstico , Displasia Ectodérmica/genética , Fenotipo , Madres , Proteína de Dominio de Muerte Asociada a Edar/genética
3.
BMC Chem ; 17(1): 65, 2023 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-37353836

RESUMEN

To find new anti-browning and whitening agents in this study, new series of isopropylquinazolinone derivatives were designed and synthesized. All derivatives were evaluated as possible tyrosinase inhibitors and compound 9q bearing 4-fluorobenzyl moieties at the R position exhibited the best potencies with an IC50 value of 34.67 ± 3.68 µM. The kinetic evaluations of 9q as the most potent derivatives recorded mix-type inhibition. Compounds 9o and 9q also exhibited potent antioxidant capacity with IC50 values of 38.81 and 40.73 µM, respectively confirming their antioxidant potential. Molecular docking studies of 9q as the most potent derivative were exacuated and it was shown that quinazolinone and acetamide moieties of compound 9q participated in interaction with critical His residues of the binding site. The obtained results demonstrated that the 9q can be considered a suitable pharmacophore to develop potent tyrosinase inhibitors.

4.
Dermatol Ther ; 35(10): e15770, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-36054253

RESUMEN

Although antibiotics are among the most commonly used treatments of acne, there are refractory cases, or they can cause some complications. Recently, leukotriene B4 has been found to play a major role in inflammatory acne lesions. This double blind, randomized clinical trial was conducted on 108 patients with acne who needed systemic therapy and referred to dermatology clinics affiliated to Shiraz University of Medical Sciences. One group (53 patients) received 100 mg doxycycline daily plus placebo and the other group (55 patients) received 100 mg daily doxycycline plus 10 mg daily montelukast. Both groups also received topical benzoyl peroxide 5% every other night. The study period was 3 months and the patients were investigated by lesion count, investigator global assessment (IGA), global acne grading system (GAGS), and Cardiff acne disability index (CADI) scoring systems. Total lesion count, inflammatory lesion count, and non-inflammatory lesion count as well as IGA and GAGS decreased in both treatment groups. At the end of the study, however, the inflammatory lesion count and IGA score reduced more significantly in the montelukast group (p = 0.018 and 0.045, respectively). In addition, the two groups were significantly different with regard to the percentage of decrease in the total lesion count, inflammatory lesions, and IGA (p = 0.033, 0.003, and 0.044, respectively). Thus, montelukast can be used as an adjuvant therapy besides other treatments of acne, especially for inflammatory lesions.


Asunto(s)
Acné Vulgar , Fármacos Dermatológicos , Acetatos , Acné Vulgar/patología , Antibacterianos , Peróxido de Benzoílo , Ciclopropanos , Método Doble Ciego , Doxiciclina/uso terapéutico , Geles/uso terapéutico , Humanos , Inmunoglobulina A/uso terapéutico , Leucotrieno B4/uso terapéutico , Quinolinas , Sulfuros , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...